Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Pfizer Inc. (PFE) is a multinational pharmaceutical and biotechnology company headquartered in New York. It researches, develops, and manufactures biopharmaceutical products for use in the ...

Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...

Pfizer has ended its development of danuglipron, its oral weight-loss drug. (Image Credits: Reuters) Pfizer said on Monday it has discontinued development of experimental weight-loss pill ...

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant. The company said Monday the stoppage comes after it ...

Pfizer has a very low valuation and a sky-high dividend yield. But this could be a broken stock, not so much a broken company. Pfizer's product sales could churn as patents expire, but the stock ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Effectiveness with low-dose doxycycline as effective as with high doses, but with greater tolerability. HealthDay News — Relative to high-dose doxycycline, low-dose doxycycline is comparably effective ...

Low-dose doxycycline showed comparable efficacy with high-dose treatment in patients with lymphocytic scarring alopecia, with a lower rate of adverse events (AEs) and related discontinuations.

Pfizer Inc has announced that it will stop developing a obesity pill called ‘danuglipron’, after safety concerns were raised during a clinical trial. According to a company’s statement, one patient ...